- Net Product Sales $2.74B in Q2:16: Increased
22% Y/Y
- REVLIMID® Net Product Sales $1.7B in Q2:16;
Increased 18% Y/Y
- 2016 Guidance Updated: REVLIMID® and Total
Net Product Sales; EPS
Celgene Corporation (NASDAQ:CELG) reported net product sales of
$2,745 million for the second quarter of 2016, a 22 percent
increase from the same period in 2015. Net product sales growth
includes a 1 percent negative impact from currency exchange
effects. Second quarter total revenue increased 21 percent to
$2,754 million compared to $2,278 million in the second quarter of
2015.
Net income for the second quarter of 2016 based on U.S. GAAP
(Generally Accepted Accounting Principles), was $598 million or
$0.75 per diluted share compared to $356 million or $0.43 per
diluted share in the second quarter of 2015. Adjusted net income
for the second quarter of 2016 was $1,152 million or $1.44 per
diluted share compared to $1,019 million or $1.23 per diluted share
for the second quarter of 2015.
“Our first-half 2016 operating results were outstanding and we
are pleased with the progress made advancing many key corporate
objectives,” said Mark J. Alles, Chief Executive Officer of Celgene
Corporation. “This strong momentum increases our confidence in our
near- and longer-term outlook as we continue to invest in
innovative research and the development of transformational
therapies for patients worldwide.”
Second Quarter 2016 Financial
Highlights
Unless otherwise stated, all comparisons are for the second
quarter of 2016 compared to the second quarter of 2015. The
adjusted operating expense categories presented below exclude
share-based employee compensation expense, upfront collaboration
expense and a litigation-related loss contingency accrual expense.
Please see the attached Reconciliation of GAAP to Adjusted Net
Income for further information.
Net Product Sales Performance
- REVLIMID® sales for the second quarter
increased 18 percent year-over-year to $1,701 million and were
driven by new patient market share gains and increased duration.
U.S. sales of $1,080 million and international sales of $621
million increased 24 percent and 9 percent year-over-year,
respectively.
- POMALYST®/IMNOVID® sales for the second
quarter were $318 million, an increase of 35 percent
year-over-year. U.S. sales were $185 million and international
sales were $133 million, an increase of 29 percent and 46 percent
year-over-year, respectively. POMALYST®/IMNOVID® sales grew due to
increased volume from duration gains.
- ABRAXANE® sales for the second quarter
were $249 million, a 2 percent increase year-over-year. U.S. sales
of $175 million increased 3 percent year-over-year. International
sales were $74 million.
- OTEZLA® sales for the second quarter
were $242 million, a 170 percent increase year-over-year. U.S.
sales were $217 million and international sales were $25 million.
Sales were driven by market share gains and increased prescriber
adoption.
- In the second quarter, all other
product sales, which include THALOMID®, ISTODAX®, VIDAZA® and an
authorized generic version of VIDAZA® drug product in the U.S.,
were $235 million compared to $242 million in the second quarter of
2015.
Research and Development (R&D)
On a GAAP basis, R&D expenses were $949 million for the
second quarter of 2016 compared to $1,110 million for the same
period in 2015. The change was primarily driven by a decrease in
upfront collaboration expenses compared to the previous year,
partially offset by early research and clinical trial activity
related to the acquisitions of Receptos, Inc. and Quanticel
Pharmaceuticals, Inc. that closed in the second half of 2015.
Adjusted R&D expenses were $601 million for the second quarter
of 2016 compared to $477 million for the second quarter of 2015.
Adjusted R&D does not include upfront collaboration expenses
but does reflect the increase in early research and clinical trial
activity.
Selling, General, and Administrative (SG&A)
On a GAAP basis, SG&A expenses were $732 million for the
second quarter of 2016 compared to $617 million for the same period
in 2015. The increase was primarily due to a loss contingency
accrual expense of $100 million related to a contractual dispute.
Adjusted SG&A expenses were $547 million for the second quarter
of 2016 compared to $541 million for the second quarter of
2015.
Cash, Cash Equivalents, and Marketable Securities
Operating cash flow was $936 million in the second quarter of
2016. Celgene ended the quarter with approximately $6.4 billion in
cash, cash equivalents and marketable securities.
In the second quarter of 2016, Celgene purchased approximately
3.4 million of its shares at a total cost of approximately $343
million. In June 2016, the share repurchase authorization was
increased by an additional authorization of $3 billion. As of June
30, 2016, the Company had approximately $5.1 billion remaining
under the stock repurchase program.
2016 Guidance
Updated
Previous 2016Guidance
Updated 2016Guidance
Net Product Sales Total $10.75B-$11.0B Approximately $11.0B
REVLIMID® Approximately $6.7B Approximately $6.8B GAAP diluted EPS
$4.26 to $4.56 $3.82 to $4.05 Adjusted diluted EPS $5.60 to $5.70
$5.70 to $5.75 GAAP operating margin Approximately 42%
Approximately 37% Adjusted operating margin Approximately 53.5%
Approximately 54.0% Weighted average diluted shares 811M 806M
Net product sales guidance for POMALYST®/IMNOVID®, ABRAXANE® and
OTEZLA® remain unchanged.
Product and Pipeline
Updates
Hematology/Oncology
- At the American Society of Clinical
Oncology (ASCO) meeting in June, pooled data from a meta-analysis
of overall survival (OS) in multiple myeloma patients receiving
REVLIMID® as maintenance treatment following autologous stem-cell
transplant were presented. An application was submitted to the
European Medicines Agency (EMA) in early June for the review of
REVLIMID® as maintenance treatment in newly diagnosed multiple
myeloma (NDMM) patients after receiving an autologous stem-cell
transplant. A decision on the application is expected in 2017. A
submission in the U.S. is expected in the second half of 2016.
- In July, the European Commission (EC)
approved REVLIMID® for the treatment of adult patients with
relapsed or refractory mantle cell lymphoma. REVLIMID® is approved
in the U.S. for the treatment of mantle cell lymphoma after relapse
or progression on two prior therapies.
- In June, the U.S. product insert for
POMALYST® was updated to include data from a pooled
pharmacokinetics analysis of patients with relapsed and/or
refractory multiple myeloma (RRMM) and impaired renal function. In
Europe, the Committee for Medicinal Products for Human Use (CHMP)
granted a positive opinion for IMNOVID® based on the same data. The
EC decision is expected in the third quarter.
- In July, Celgene disclosed the top-line
results of the phase III REMARC trial evaluating REVLIMID® as
maintenance therapy compared with placebo in patients with diffuse
large B-cell lymphoma responding to treatment with rituximab in
combination with standard chemotherapy. The full data set will be
presented at a future medical congress.
- In July, Celgene’s partner Juno
Therapeutics provided preliminary data from the ongoing phase I
trial with JCAR017 in patients with adult non-Hodgkin lymphoma
(NHL). In ten patients evaluable for efficacy, an overall response
rate of 80 percent and a complete response rate of 70 percent were
seen. In thirteen patients evaluable for safety, the rate of severe
neurotoxicity was 15 percent and the rate of cytokine release
syndrome was zero percent. An update of the trial data is expected
later in the year.
- The FUSIONTM program evaluating
durvalumab in hematological malignancies continues to advance with
six early-stage trials enrolling. The trials are evaluating
durvalumab as a single agent or in combination with novel agents in
NDMM, RRMM, myelodysplastic syndromes, acute myeloid leukemia, NHL
and chronic lymphocytic leukemia.
- A phase II trial with CC-486 in
combination with pembrolizumab in previously treated locally
advanced or metastatic non-small cell lung cancer completed
enrollment in the second quarter.
Inflammation & Immunology
- Long-term data from the PALACE program
evaluating OTEZLA® in moderate-to-severe psoriatic arthritis were
presented at the European League Against Rheumatism (EULAR) meeting
in June. Included was three-year pooled efficacy and safety data
from the phase III PALACE program, as well as pooled data on
fatigue, HAQ-DI and BASDAI from PALACE 1-3.
- The phase II proof-of-concept trial
evaluating OTEZLA® in atopic dermatitis has completed. Celgene is
evaluating the data to determine next steps. The data will be
published at a later date.
- In May, the phase II TOUCHSTONE trial
evaluating ozanimod induction and maintenance in patients with
moderate-to-severe ulcerative colitis was published in The New
England Journal of Medicine. Histologic data from the phase II
TOUCHSTONE trial were presented at the Digestive Disease Week
meeting in May. The phase III TRUE NORTH trial evaluating ozanimod
in patients with moderate-to-severe ulcerative colitis continues to
enroll with data expected in 2018.
- The registration-enabling endoscopy
trial (CD-001) with GED-0301 in patients with active Crohn's
disease completed enrollment. Top-line data from the 12-week
portion of the trial is expected in the second half of 2016.
Business Update
- In July, Celgene announced a strategic
collaboration with Jounce Therapeutics, Inc. The collaboration
includes options on Jounce’s lead product candidate, JTX-2011,
targeting ICOS (the Inducible T cell CO-Stimulator), and up to four
early-stage programs to be selected from a defined pool of B cell,
T regulatory cell and tumor-associated macrophage targets emerging
from Jounce’s research platform, and an additional option on a
Jounce checkpoint immuno-oncology program.
- In May, Celgene and Agios
Pharmaceuticals, Inc. entered into a new global strategic
collaboration for the discovery, development and commercialization
of novel metabolic immuno-oncology therapies based on Agios'
innovative cellular metabolism research platform. In addition,
Celgene transferred global development and commercialization rights
to the AG-120 program to Agios.
Second Quarter 2016 Conference Call and
Webcast Information
Celgene will host a conference call to discuss the second
quarter of 2016 operational and financial performance on Thursday,
July 28, 2016, at 9 a.m. ET. The conference call will be available
by webcast at www.celgene.com. An audio replay of the call will be
available from noon July 28, 2016, until midnight ET August 4,
2016. To access the replay in the U.S., dial (855) 859-2056;
outside the U.S. dial (404) 537-3406. The participant passcode is
43057627.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, FaceBook and
YouTube.
About REVLIMID®
In the U.S., REVLIMID® (lenalidomide) in combination with
dexamethasone is indicated for the treatment of patients with
multiple myeloma. REVLIMID® is indicated for patients with
transfusion-dependent anemia due to Low- or Intermediate-1-risk
myelodysplastic syndromes (MDS) associated with a deletion 5q
cytogenetic abnormality with or without additional cytogenetic
abnormalities. REVLIMID® is approved in the U.S. for the treatment
of patients with mantle cell lymphoma (MCL) whose disease has
relapsed or progressed after two prior therapies, one of which
included bortezomib. Limitations of Use: REVLIMID® is not indicated
and is not recommended for the treatment of chronic lymphocytic
leukemia (CLL) outside of controlled clinical trials.
About ABRAXANE®
In the U.S., ABRAXANE® for Injectable Suspension (paclitaxel
protein-bound particles for injectable suspension) (albumin-bound)
is indicated for the treatment of metastatic breast cancer after
failure of combination chemotherapy for metastatic disease or
relapse within six months of adjuvant chemotherapy. Prior therapy
should have included an anthracycline unless clinically
contraindicated. ABRAXANE® is indicated for the first-line
treatment of locally advanced or metastatic non-small cell lung
cancer, in combination with carboplatin, in patients who are not
candidates for curative surgery or radiation therapy. ABRAXANE® is
also indicated for the first-line treatment of metastatic
adenocarcinoma of the pancreas in combination with gemcitabine.
About POMALYST®
In the U.S., POMALYST® (pomalidomide) is indicated for patients
with multiple myeloma who have received at least two prior
therapies including lenalidomide and a proteasome inhibitor and
have demonstrated disease progression on or within 60 days of
completion of the last therapy.
About OTEZLA®
In the U.S., OTEZLA® (apremilast) is indicated for the treatment
of adult patients with active psoriatic arthritis. OTEZLA® is
indicated in the U.S. for the treatment of patients with moderate
to severe plaque psoriasis who are candidates for phototherapy or
systemic therapy.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
In addition to financial information prepared in accordance with
U.S. GAAP, this press release also contains adjusted financial
measures that we believe provide investors and management with
supplemental information relating to operating performance and
trends that facilitate comparisons between periods and with respect
to projected information. These adjusted financial measures are
non-GAAP and should be considered in addition to, but not as a
substitute for, the information prepared in accordance with U.S.
GAAP. We typically exclude certain GAAP items that management does
not believe affect our basic operations and that do not meet the
GAAP definition of unusual or non-recurring items. Other companies
may define these measures in different ways. See the attached
Reconciliations of GAAP to Adjusted Net Income for explanations of
the amounts excluded and included to arrive at the adjusted
measures for the three- and six-month periods ended June 30, 2016
and 2015, and for the projected amounts for the year ending
December 31, 2016.
Celgene Corporation and
Subsidiaries
Condensed Consolidated Statements of Income
(Unaudited) (In millions, except per share data)
Three-Month Periods Ended
Six-Month Periods Ended June 30, June 30, 2016 2015 2016 2015
Net product sales $ 2,744.5 $ 2,254.1 $ 5,239.2 $ 4,309.3
Other revenue 9.8 23.7 26.7 49.3 Total revenue 2,754.3 2,277.8
5,265.9 4,358.6 Cost of goods sold (excluding amortization
of acquired intangible assets) 110.9 100.8 216.8 204.8 Research and
development 948.7 1,110.0 1,681.9 1,616.0 Selling, general and
administrative 732.1 616.8 1,275.1 1,146.0 Amortization of acquired
intangible assets 174.8 63.7 266.6 127.3 Acquisition related
charges and restructuring, net (35.9) (29.3) 0.3 (10.3) Total costs
and expenses 1,930.6 1,862.0 3,440.7 3,083.8 Operating
income 823.7 415.8 1,825.2 1,274.8 Interest and investment
income, net 7.2 8.8 14.0 17.8 Interest (expense) (123.3) (48.3)
(245.2) (97.5) Other income (expense), net (12.5) 94.5 22.7 102.8
Income before income taxes 695.1 470.8 1,616.7 1,297.9
Income tax provision 96.9 114.6 217.8 222.8 Net
income $ 598.2 $ 356.2 $ 1,398.9 $ 1,075.1 Net income
per common share: Basic $ 0.77 $ 0.45 $ 1.80 $ 1.35 Diluted $ 0.75
$ 0.43 $ 1.74 $ 1.30 Weighted average shares: Basic 775.6
793.0 778.1 796.0 Diluted 801.5 825.3 804.7 829.7
June 30, December 31, 2016 2015
Balance sheet items: Cash,
cash equivalents & marketable securities $ 6,403.7 $ 6,551.9
Total assets* 26,562.0 26,964.4 Long-term debt* 14,312.1 14,161.4
Total stockholders' equity 5,548.8 5,919.0 * Total assets
and long-term debt as of December 31, 2015 have been adjusted to
reflect the retroactive adoption of ASU 2015-03 in the first
quarter of 2016. ASU 2015-03 requires the presentation of debt
issuance costs as a reduction of long-term debt.
Celgene
Corporation and Subsidiaries Reconciliation of GAAP to
Adjusted Net Income (In millions, except per share data)
Three-Month Periods Ended Six-Month Periods
Ended June 30, June 30, 2016 2015 2016 2015 Net income -
GAAP $ 598.2 $ 356.2 $ 1,398.9 $ 1,075.1 Before tax
adjustments: Cost of goods sold (excluding amortization of acquired
intangible assets): Share-based compensation expense (1) 8.6 8.1
17.6 14.8 Research and development: Share-based compensation
expense (1) 63.9 63.6 126.1 119.8 Upfront collaboration expense (2)
284.0 569.5 364.0 588.5 Selling, general and administrative:
Share-based compensation expense (1) 85.0 76.0 160.3 141.9
Litigation-related loss contingency accrual expense (3) 100.0 -
100.0 - Amortization of acquired intangible assets (4) 174.8
63.7 266.6 127.3 Acquisition related (gains) charges and
restructuring, net: Change in fair value of contingent
consideration (5) (43.7) (29.3) (10.7) (10.3) Restructuring charges
(6) 7.8 - 11.0 - Net income tax adjustments (7) (126.7)
(89.0) (217.6) (147.3) Net income - Adjusted $ 1,151.9 $ 1,018.8 $
2,216.2 $ 1,909.8 Net income per common share - Adjusted
Basic $ 1.49 $ 1.28 $ 2.85 $ 2.40 Diluted $ 1.44 $ 1.23 $ 2.75 $
2.30 In addition to financial information prepared in
accordance with U.S. GAAP, this press release also contains
adjusted financial measures that we believe provide investors and
management with supplemental information relating to operating
performance and trends that facilitate comparisons between periods
and with respect to projected information. These adjusted financial
measures are non-GAAP and should be considered in addition to, but
not as a substitute for, the information prepared in accordance
with U.S. GAAP. We typically exclude certain GAAP items that
management does not believe affect our basic operations and that do
not meet the GAAP definition of unusual or non-recurring items.
Other companies may define these measures in different ways.
Explanation of adjustments: (1) Exclude share-based compensation
expense totaling $157.5 for the three-month period ended June 30,
2016 and $147.7 for the three-month period ended June 30, 2015.
Exclude share-based compensation expense totaling $304.0 for the
six-month period ended June 30, 2016 and $276.5 for the six-month
period ended June 30, 2015. (2) Exclude upfront payment
expense for research and development collaboration arrangements.
(3) Exclude loss contingency accrual expense related to a
contractual dispute. (4) Exclude amortization of intangible
assets acquired in the acquisitions of Pharmion Corp., Gloucester
Pharmaceuticals, Inc. (Gloucester), Abraxis BioScience Inc.
(Abraxis), Celgene Avilomics Research, Inc. (Avila), and Quanticel
Pharmaceuticals, Inc. (Quanticel). The excluded amortization
expense for the three- and six-month periods ended June 30, 2016
includes $83.1 million related to the impairment of an intangible
asset acquired in the Avila acquisition. (5) Exclude changes
in the fair value of contingent consideration related to the
acquisitions of Gloucester, Abraxis, Avila, Nogra Pharma Limited
and Quanticel. (6) Exclude restructuring charges related to
our relocation of certain operations into our two Summit, NJ
locations as well as costs associated with certain headcount
reductions. (7) Net income tax adjustments reflect the
estimated tax effect of the above adjustments and the impact of
certain other non-operating tax adjustments, including the effects
of acquisition related matters, adjustments to the amount of
unrecognized tax benefits, and adjustments related to the gain on
the sale of certain assets.
Celgene Corporation and
Subsidiaries Reconciliation of Full-Year 2016 Projected GAAP
to Adjusted Net Income (In millions, except per share
data) Range Low High
Projected net income - GAAP (1) $ 3,074.9 $ 3,266.5
Before tax adjustments: Cost of goods sold (excluding amortization
of acquired intangible assets): Share-based compensation expense
37.0 35.2 Research and development: Share-based compensation
expense 263.4 250.9 Upfront collaboration expense 601.0 601.0
Selling, general and administrative: Share-based
compensation expense 334.8 318.9 Litigation-related loss
contingency accrual expense 100.0 100.0 Amortization of
acquired intangible assets 458.2 418.6 Acquisition related
(gains) charges and restructuring, net: Change in fair value of
contingent consideration 43.7 39.5 Restructuring charges 30.0 15.0
Net income tax adjustments (348.8) (411.1)
Projected net income - Adjusted $ 4,594.2 $ 4,634.5
Projected net income per diluted common share - GAAP $ 3.82 $ 4.05
Projected net income per diluted common share - Adjusted $
5.70 $ 5.75 Projected weighted average diluted shares 806.0
806.0 (1) Our projected 2016 earnings do not include the
effect of any business combinations, collaboration agreements,
asset acquisitions, intangible asset impairments, additional
litigation-related loss contingency accruals or changes in the fair
value of our CVRs issued as part of the acquisition of Abraxis that
may occur after the day prior to the date of this press release.
Celgene Corporation and Subsidiaries Net Product
Sales (In millions)
Three-Month Periods Ended June 30, % Change
2016 2015 Reported Operational(1)
Currency(2)
REVLIMID® U.S. $ 1,079.6 $
872.6 23.7% 23.7% 0.0% International 621.2 571.4 8.7% 10.9% (2.2)%
Worldwide 1,700.8 1,444.0 17.8% 18.7% (0.9)%
ABRAXANE® U.S. 174.7 169.8 2.9% 2.9% 0.0%
International 74.4 74.4 0.0% 2.4% (2.4)% Worldwide 249.1 244.2 2.0%
2.7% (0.7)%
POMALYST®/IMNOVID®
U.S. 184.9 143.6 28.8% 28.8% 0.0% International 132.8 90.9 46.1%
43.2% 2.9% Worldwide 317.7 234.5 35.5% 34.4% 1.1%
OTEZLA®(3) U.S. 216.8 84.7 N/A N/A N/A International
25.1 5.0 N/A N/A N/A Worldwide 241.9 89.7 N/A N/A N/A
VIDAZA® U.S. 3.6 5.6 (35.7)% (35.7)% 0.0%
International 150.5 146.5 2.7% 5.6% (2.9)% Worldwide 154.1 152.1
1.3% 4.1% (2.8)%
azacitidine for injection U.S. 21.7
22.3 (2.7)% (2.7)% 0.0% International - - N/A N/A N/A Worldwide
21.7 22.3 (2.7)% (2.7)% 0.0%
THALOMID® U.S.
23.3 33.8 (31.1)% (31.1)% 0.0% International 14.4 14.1 2.1% 5.4%
(3.3)% Worldwide 37.7 47.9 (21.3)% (20.3)% (1.0)%
ISTODAX® U.S. 18.9 17.0 11.2% 11.2% 0.0%
International 1.8 0.9 100.0% 107.1% (7.1)% Worldwide 20.7 17.9
15.6% 16.0% (0.4)%
All Other U.S. - 0.9 N/A N/A N/A
International 0.8 0.6 N/A N/A N/A Worldwide 0.8 1.5 N/A N/A N/A
Total Net Product Sales U.S. 1,723.5 1,350.3 27.6%
27.6% 0.0% International 1,021.0 903.8 13.0% 14.6% (1.6)% Worldwide
$ 2,744.5 $ 2,254.1 21.8% 22.5% (0.7)% (1) - Operational
includes impact from both volume and price (2) - Currency includes
the impact from both foreign exchange rates and hedging activities
(3) - OTEZLA® was approved in the U.S. for Psoriatic Arthritis in
March 2014 and approved in the U.S. for Psoriasis in September
2014. OTEZLA® was approved for Psoriatic Arthritis and Plaque
Psoriasis in the EU in January 2015.
Celgene Corporation and
Subsidiaries Net Product Sales (In millions)
Six-Month Periods
Ended June 30, % Change 2016 2015
Reported Operational(1)
Currency(2)
REVLIMID® U.S. $ 2,076.1 $ 1,683.4 23.3% 23.3% 0.0%
International 1,198.3 1,103.5 8.6% 11.8% (3.2)% Worldwide 3,274.4
2,786.9 17.5% 18.8% (1.3)%
ABRAXANE® U.S.
318.5 328.9 (3.2)% (3.2)% 0.0% International 155.5 138.7 12.1%
14.5% (2.4)% Worldwide 474.0 467.6 1.4% 2.1% (0.7)%
POMALYST®/IMNOVID® U.S. 355.6 272.0
30.7% 30.7% 0.0% International 236.1 161.0 46.6% 45.2% 1.4%
Worldwide 591.7 433.0 36.7% 36.2% 0.5%
OTEZLA®(3) U.S. 391.6 144.1 N/A N/A N/A International
45.9 5.9 N/A N/A N/A Worldwide 437.5 150.0 N/A N/A N/A
VIDAZA® U.S. 7.1 11.5 (38.3)% (38.3)% 0.0%
International 293.7 284.2 3.3% 7.3% (4.0)% Worldwide 300.8 295.7
1.7% 5.6% (3.9)%
azacitidine for injection U.S. 40.2
42.9 (6.3)% (6.3)% 0.0% International - - N/A N/A N/A Worldwide
40.2 42.9 (6.3)% (6.3)% 0.0%
THALOMID® U.S.
50.8 66.2 (23.3)% (23.3)% 0.0% International 27.9 28.6 (2.4)% 2.0%
(4.4)% Worldwide 78.7 94.8 (17.0)% (15.7)% (1.3)%
ISTODAX® U.S. 35.6 32.2 10.6% 10.6% 0.0%
International 3.6 2.2 63.6% 72.5% (8.9)% Worldwide 39.2 34.4 14.0%
14.6% (0.6)%
All Other U.S. 1.2 2.7 N/A N/A N/A
International 1.5 1.3 N/A N/A N/A Worldwide 2.7 4.0 N/A N/A N/A
Total Net Product Sales U.S. 3,276.7 2,583.9 26.8%
26.8% 0.0% International 1,962.5 1,725.4 13.7% 16.4% (2.7)%
Worldwide $ 5,239.2 $ 4,309.3 21.6% 22.7% (1.1)% (1) - Operational
includes impact from both volume and price (2) - Currency includes
the impact from both foreign exchange rates and hedging activities
(3) - OTEZLA® was approved in the U.S. for Psoriatic Arthritis in
March 2014 and approved in the U.S. for Psoriasis in September
2014. OTEZLA® was approved for Psoriatic Arthritis and Plaque
Psoriasis in the EU in January 2015.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160728005734/en/
Investors:Patrick E. Flanigan III, 908-673-9969Corporate Vice
PresidentInvestor RelationsorMedia:Brian P. Gill, 908-673-9530Vice
PresidentCorporate Communications
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024